FDA OKs BrainLab radiosurgery planning software

TriMed Staff | | Health Imaging | Oncology Imaging
BrainLab has received 510(k) clearance from the FDA for its HybridArc radiosurgery planning software.

HybridArc expands upon the Dynamic Arc stereotactic treatment technique to offer high dose conformity to the target. The software package uses an adaptive dose calculation matrix that takes into account the different parameters affecting dose distribution to provide precision when opting for stereotactic radiosurgery.

According to Munich-based BrainLab, HybridArc can be deployed in hospitals that either have Linac treatment technology or those that want to gain the capability of radiosurgery without a hardware upgrade. Treatments can be delivered on most Linac-based radiosurgery systems.

TriMed Staff

Related Content

Imaging may be misleading when determining the success of cancer treatment
Prostate cancer radiotherapy timeline can be safely shortened
New radiopharmaceutical targeted at gastrointenstinal cancers yields impressive results
New PET method combines antibody with radioactive isotope to improve lung cancer detection
VI-RADS threshold, imaging features predict bladder cancer invasiveness with nearly 100% accuracy
PHOTO GALLERY: thyroid nodule imaging

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.